heidi merethe hoff naken sorted by

relevance

During this 6 year period she will coordinate both the randomized part and the follow up part of the project.

continuing anti-TNF in UC patients in remiss.

To assess UC-related events hospitalizations, procedures ,cost-effectiveness and effect on health-related quality of life QoL after two years of randomized treatmen Collaboration National coordinating center Ingrid Prytz Berset is the national coordinating investigator of the BIOSTOP study.

About the project In the BIOSTOP Study ulcerative colitis patients in remission after at least one year anti-TNF maintenance therapy will be included.

During the randomization period, patients will be monitored by repeated symptom scoring and faecal calprotectin.

If clinical remission is confirmed by symptom score and faecal calprotectin, a full ileocolonoscopy is performed.

National cooperating centers and other cooperating partners Hospitals and centers from all parts of Norway and all four health regions will participate in the BIOSTOP Study.

To identify factors predictive for successful restart of anti-TNF in patients experiencing a relapse Resource utilization, cost-effectiveness and patients reported outcome objectives• A prospective, open randomized, parallel-Group study to evaluate the outcome of discontinuing vs.

Control group patients, and intervention group patients who has restarted anti-TNF, will in addition be regularly monitored by anti-TNF drug concentration and antibody measurements.

The study will be organized and conducted in cooperation with Norwegian Clinical Research Infrastructures Network NORCRIN at the Norwegian University of Science and Technology NTNU.

Patients will be openly randomized to either discontinuing anti-TNF intervention group or continuing anti-TNF control group for 2 years.

.